KRAS and colorectal neoplasm: KRAS wild-type colorectal tumors are usually sensitive to EGFR blockade, e.g., cetuximab and panitumumab are one of the mainstays of targeted therapy for colorectal cancer, but resistance almost always develops within a few months of initiating therapy.